EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users

Marleen E Jansen iD, Tessel Rigter iD, Thom M C Fleur, Patrick C Souverein iD, W M Monique Verschuren, Susanne J Vijverberg, Jesse J Swen iD, Wendy Rodenburg, Martina C Cornel iD

Genes · 10.02.2023 · 14 (2) · 456

DOI: 10.3390/genes14020456 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, online erschienen am 10.02.2023. Verfasst von Marleen E Jansen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, Amsterdam Public Health Research Institute, Personalized Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Sect…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Public Health and the Environment (RIVM).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients at high risk for adverse drug reactions. We aim to investigate the clinical validity and utility of pre-emptive pharmacogenomics screening in primary care, with SLCO1B1 c.521T>C as a risk factor for statin-induced adverse drug reactions. The focus was on changes in therapy as a proxy for adverse drug reactions observed in statin-users in a population-based Dutch cohort. In total, 1136 statin users were retrospectively genotyped for the SLCO1B1 c.521T>C polymorphism (rs4149056) and information on their statin dispensing was evaluated as cross-sectional research. Approximately half of the included participants discontinued or switched their statin treatment within three years. In our analyses, we could not confirm an association between the SLCO1B1 c.521T>C genotype and any change in statin therapy or arriving at a stable dose sooner in primary care. To be able to evaluate the predictive values of SLCO1B1 c.521T>C genotype on adverse drug reactions from statins, prospective data collection of actual adverse drug reactions and reasons to change statin treatment should be facilitated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsDrug-Related Side Effects and Adverse ReactionsHumansCross-Sectional StudiesRetrospective StudiesPolymorphism, Single NucleotideLiver-Specific Organic Anion Transporter 1

Stichwörter der Autor:innen

adverse drug reactionspharmacogenomicsprimary carescreeningstatins

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsSLCO1B1 protein, humanLiver-Specific Organic Anion Transporter 1

Autor:innen und Institutionen

  • Department of Clinical Genetics, Amsterdam Public Health Research Institute, Personalized Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Section Community Genetics, 1081 HV Amsterdam, The Netherlands.
  • Centre for Health Protection, National Institute for Public Health and the Environment, 3721 MA Bilthoven, The Netherlands.
  • Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, The Netherlands.
  • Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment, 3721 MA Bilthoven, The Netherlands.
  • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands.
  • Department of Pulmonary Medicine and Amsterdam Public Health Research Institute, Personalized Medicine, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

ORCID-Profile: Marleen E Jansen, Tessel Rigter, Patrick C Souverein, Jesse J Swen, Martina C Cornel

Förderung

  • National Institute for Public Health and the Environment (RIVM)

Zitieren

APA

Jansen, M. E., Rigter, T., Fleur, T. M. C., Souverein, P. C., Verschuren, W. M. M., Vijverberg, S. J., Swen, J. J., Rodenburg, W., & Cornel, M. C. (2023). Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users. Genes, 14(2), 456. https://doi.org/10.3390/genes14020456

Vancouver

Jansen ME, Rigter T, Fleur TMC, Souverein PC, Verschuren WMM, Vijverberg SJ, et al. Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users. Genes. 2023;14(2):456. doi:10.3390/genes14020456

BibTeX
@article{Jansen2023,
  author = {Jansen, Marleen E and Rigter, Tessel and Fleur, Thom M C and Souverein, Patrick C and Verschuren, W M Monique and Vijverberg, Susanne J and Swen, Jesse J and Rodenburg, Wendy and Cornel, Martina C},
  title = {Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users},
  journal = {Genes},
  year = {2023},
  volume = {14},
  number = {2},
  pages = {456},
  doi = {10.3390/genes14020456}
}
Kostenlos starten →